Urinary anti-infective agent

Did You Know?

• Nitrofurantoin emerged as the first practical and safe urinary antimicrobial agent, but with a limited spectrum of activity.
• Fluoroquinolones emerged during the 1980s and were recommended as an alternative when resistance to TMP/SMX reaches 10% or higher.
• Beta-lactam antibiotics and TMP/SMX became available for UTI therapy in the 1970s.

Types of urinary anti-infective agent

Urinary antiseptics are divided into bactericidal and bacteriostatic agents. Nitrofurantoin, a first-line agent for simple cystitis with 88% to 92% efficacy, is also used prophylactically for long-term UTIs. It acts against gram-positive and gram-negative bacteria through mechanisms including inhibition of ribosomal translation, bacterial DNA damage, and interference with the citric acid cycle, though the specific role of each mechanism is not fully understood. When metabolized, nitrofurantoin converts to a reactive intermediate that attacks bacterial ribosomes, inhibiting protein synthesis. It is taken orally with minimal systemic absorption; common adverse reactions include brown urine discoloration, nausea, vomiting, loss of appetite, rash, and peripheral neuropathy. Fosfomycin, a phosphonic acid bactericidal agent, is a first-line treatment for acute simple cystitis with a 91% cure rate, administered orally as a single dose or every three days for complicated UTIs. It inhibits bacterial wall synthesis by inactivating pyruvyl transferase and acts against gram-positive and gram-negative bacteria; side effects may include headache, dizziness, nausea, vomiting, and abdominal cramps. Beta-lactam antibiotics, such as cephalosporins and penicillin, are second-line options for UTIs due to lower effectiveness and potential adverse effects. They bind to penicillin-binding proteins via their beta-lactam rings, disrupting cell wall synthesis and causing cell death.

Renal dysfunction

Kidney disease can alter drug elimination, absorption, and distribution, raising the risk of toxicity or suboptimal effects, so dosage adjustments are needed when therapeutic serum levels are not achieved. The choice of urinary anti-infective agents for patients with renal dysfunction is generally similar to that for those with normal kidney function, but when glomerular filtration rate falls below 20 mL/min, dosage adjustment becomes necessary. Nitrofurantoin is contraindicated in patients with an estimated GFR below 30 mL/min/1.73m² because accumulation increases side effects and risk of treatment failure. For TMP/SMX, creatinine clearance below 50 mL/min may reduce SMX urine concentrations to subtherapeutic levels, so a reduced dosage of TMP alone is recommended.

Pregnancy

Pregnant women with UTIs face higher risks of recurrent bacteriuria and pyelonephritis, and untreated infections can lead to preterm birth and low birth weight. Empiric antibiotic treatment for acute cystitis often includes amoxicillin-clavulanate and fosfomycin, while parenteral beta-lactams are preferred for acute pyelonephritis; a five- to seven-day course is typical to minimize fetal exposure. Penicillins, cephalosporins, and fosfomycin are safe during pregnancy. Nitrofurantoin is usually avoided in the first trimester due to uncertain associations with congenital anomalies, and TMP/SMX is avoided because of potential impaired folate metabolism and neural tube defects; both are used only as last resort when alternatives are contraindicated. Fluoroquinolones are avoided due to bone and cartilage toxicity in developing fetuses.

Pediatrics

UTI in pediatric patients affects about 7% of fevered infants and children; untreated infection can ascend to the kidneys, causing acute pyelonephritis, hypertension, kidney scarring, and end-stage kidney disease. Antibiotic choice and duration depend on UTI type, with dosages weight-dependent. For children older than two months, oral or parenteral cephalosporins are first-line; second-line options include amoxicillin-clavulanate, nitrofurantoin, TMP/SMX, and ciprofloxacin. Simple cystitis is treated with a five-day oral course of cephalexin. For suspected pyelonephritis, a ten-day regimen with a third-generation cephalosporin such as cefdinir is recommended; if second-line therapy is needed, ciprofloxacin is preferred. Nitrofurantoin may be inadequate for upper tract infections, and TMP/SMX and amoxicillin-clavulanate require caution due to kidney scarring risk. Systemic fluoroquinolones are not appropriate in children because of potential musculoskeletal toxicity.